This Healthcare ‘Watchdog’ Is No Friend Of Coronavirus Patients
Finally, there’s a bit of good news in the fight against COVID-19. The Food and Drug Administration issued an “emergency use authorization” for remdesivir, an anti-viral drug that could help coronavirus patients recover faster. The medicine isn’t a silver bullet, but it’s the first therapy that has shown success in clinical trials. Yet one self-styled healthcare watchdog seems determined to rain on the parade. The Institute for Clinical and Economic Review, better known as ICER, routinely analyzes the “value” that new drugs provide. On the same day that the FDA ...